1. Home
  2. News
  3. Immutep Ltd
  4. Japanese patent granted for LAG-3 antibody LAG525
More Immutep Ltd news
Immutep LtdASX: IMM

Japanese patent granted for LAG-3 antibody LAG525

Mar 18, 2022 at 4:56 AM EDT · Issued by Immutep Ltd

Filed with ASX · Mar 18, 2022 at 4:56 AM EDT · 2 pages · English

On 6ix: 6ix.com/news/japanese-patent-granted-for-lag-3-antibody-lag525

Immutep Ltd on 6ix

Story so far

  • Immutep receives FDA feedback for Efti development in MBCMar 10, 2022
  • Australian Patent Granted for Efti with PD-1 InhibitorsFeb 11, 2022
  • Immutep granted Chinese Patent for eftilagimod alphaNov 2, 2021

Earlier from Immutep

  • Immutep receives FDA feedback for Efti development in MBCMar 9, 2022
  • Australian Patent Granted for Efti with PD-1 InhibitorsFeb 11, 2022
  • Immutep Advances IMP761 ManufacturingDec 15, 2021
  • Good safety reported from 1st five patients in INSIGHT-003Dec 1, 2021
  • Phase II TACTI-002 trial recruitment successfully completedNov 18, 2021

Later from Immutep

  • Immutep announces publication of ELCC 2022 abstractMar 23, 2022
  • Efti with Keytruda shows encouraging activity in lung cancerMar 29, 2022
  • Immutep to announce new TACTI-002 data at ASCO 2022Apr 27, 2022
  • New & significant data from AIPAC phase 2b trial in MBCMay 4, 2022
  • Immutep announces publication of ASCO 2022 abstractsMay 26, 2022
All Immutep news releases↗

Follow Immutep into a list and get an email when it puts out news.

Follow Immutep
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer